(S (NP-SBJ (NP (NN Oct2) (NN transactivation)) (PP (IN from) (NP (DT a) (JJ remote) (NN enhancer) (NN position)))) (VP (VBZ requires) (NP (DT a) (JJ B-cell-restricted) (NN activity))) (. .))
(S (NP-SBJ (JJ Previous) (NN cotransfection) (NNS experiments)) (VP (VBD had) (VP (VBN demonstrated) (SBAR (IN that) (S (NP-SBJ (NP (JJ ectopic) (NN expression)) (PP (IN of) (NP (DT the) (JJ lymphocyte-specific) (NN transcription) (NN factor) (NN Oct2)))) (VP (MD could) (ADVP (RB efficiently)) (VP (VB activate) (NP (NP (DT a) (NN promoter)) (VP (VBG containing) (NP (DT an) (NN octamer) (NN motif)))))))))) (. .))
(S (NP-SBJ-18 (NN Oct2) (NN expression)) (VP (VBD was) (ADJP-PRD (JJ unable) (S (NP-SBJ (-NONE- *-18)) (VP (TO to) (VP (VB stimulate) (NP (NP (DT a) (JJ multimerized) (NN octamer) (NN enhancer) (NN element)) (PP (IN in) (NP (NN HeLa) (NNS cells)))))))) (, ,) (ADVP (RB however))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN tested) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NN Oct2) (VBZ isoforms)) (VP (VBN generated) (NP (-NONE- *)) (PP (IN by) (NP-LGS (JJ alternative) (NN splicing))))))) (PP (IN for) (NP (DT the) (NN capability) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB activate) (NP (DT an) (NN octamer) (NN enhancer)) (PP (IN in) (NP-COOD (NP (JJ nonlymphoid) (NNS cells)) (CC and) (NP (DT a) (NN B-cell) (NN line))))))))))) (. .))
(S (NP-SBJ (PRP$ Our) (NNS analyses)) (VP (VBP show) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (JJ several) (NN Oct2) (NNS isoforms)) (VP (MD can) (VP (VB stimulate) (PP (IN from) (NP (DT a) (JJ remote) (NN position))))))) (CC but) (SBAR (IN that) (S (NP-SBJ-20 (DT this) (NN stimulation)) (VP (VBZ is) (VP (JJ restricted) (NP (-NONE- *-20)) (PP (TO to) (NP (NN B) (NNS cells))))))))) (. .))
(S (NP-SBJ (DT This) (NN result)) (VP (VBZ indicates) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP-COOD (CC either) (NP (DT a) (JJ B-cell-specific) (NN cofactor)) (CC or) (NP (NP (DT a) (JJ specific) (NN modification)) (PP (IN of) (NP-COOD (NP (DT a) (NN cofactor)) (CC or) (NP (DT the) (NN Oct2) (NN protein))))))) (PP (IN in) (NP (JJ Oct2-mediated) (NN enhancer) (NN activation))))) (. .))
(S (NP-SBJ (JJ Mutational) (NNS analyses)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ carboxy-terminal) (NN domain)) (PP (IN of) (NP (NN Oct2)))) (VP (VBZ is) (ADJP-PRD (JJ critical) (PP (IN for) (NP (NN enhancer) (NN activation)))))))) (. .))
(S (ADVP (RB Moreover)) (, ,) (NP-SBJ-21 (DT this) (NN domain)) (VP (VBD conferred) (NP (NN enhancing) (NN activity)) (SBAR-TMP (ADVP-23 (WRB when)) (S (NP-SBJ-22 (-NONE- *-21)) (VP (VBN fused) (NP (-NONE- *-22)) (PP (TO to) (NP (NP (DT the) (NN Oct1) (NN protein)) (, ,) (SBAR (WHNP-24 (WDT which)) (S (NP-SBJ-25 (-NONE- *T*-24)) (PP (IN by) (NP (PRP itself))) (VP (VBD was) (ADJP-PRD (JJ unable) (S (NP-SBJ (-NONE- *-25)) (VP (TO to) (VP (VB stimulate) (PP (IN from) (NP (DT a) (JJ remote) (NN position)))))))))))) (ADVP (-NONE- *T*-23)))))) (. .))
(S (NP-SBJ-COOD (NP (NP (DT The) (JJ glutamine-rich) (NN activation) (NN domain)) (ADJP (JJ present) (PP (IN in) (NP (NP (DT the) (JJ amino-terminal) (NN portion)) (PP (IN of) (NP (NN Oct2))))))) (CC and) (NP (DT the) (NN POU) (NN domain))) (VP (VBP contribute) (ADVP (RB only) (RB marginally)) (PP (TO to) (NP (DT the) (NN transactivation) (NN function))) (PP (IN from) (NP (DT a) (JJ distal) (NN position)))) (. .))
